When Frequency Therapeutics scored $80 million in cash from Astellas to jumpstart an alliance, the biotech cautiously pointed to Phase I/II data bolstering hope that they might indeed have a groundbreaking regenerative medicine approach to restoring hearing, leaning on research done by Bob Langer and Jeff Karp out of MIT around progenitor cell activation. Newly … Continue reading Hearing loss specialists at Frequency pin the blame for PhIIa flop on trial design — but they couldn’t stem a freefall in share price